JASPER THERAPEUTICS, INC. 60,000,000 Shares of Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • January 25th, 2023 • Jasper Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 60,000,000 shares (the “Firm Shares”) of the Company’s voting common stock, $0.0001 par value per share (the “Common Stock”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional 9,000,000 shares of Common Stock (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
